Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse.

ABSTRACT:

Importance

The optimal treatment approach to patients with acute myeloid leukemia (AML) who relapse after an allogeneic hematopoietic cell transplant (allo-HCT) remains elusive. No randomized clinical trial comparing survival outcomes of a second allo-HCT (allo-HCT2) vs donor lymphocyte infusion (DLI) has been conducted to date.

Objective

To compare overall survival (OS) after an allo-HCT2 or DLI in relapsed AML after a first allo-HCT.

Design, setting, and participants

A retrospective registry study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation involving 418 adults who received an allo-HCT2 (n = 137) or DLI (n = 281) for postallograft-relapsed AML. Analysis was assessed on the principle of intent-to-first received i

SUBMITTER: Kharfan-Dabaja MA 

PROVIDER: S-EPMC6143013 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature